Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

Video

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.

Related Videos
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Video 6 - "Shared Decision Making and Multidisciplinary Collaboration in the Evolving HR+/HER2- Early-Stage Breast Cancer Landscape"
Related Content
Michael Wang, MD

Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL

May 2nd 2024
Article
Lori A. Leslie, MD

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023
Podcast
stock.adobe.com

B-Cell Receptor Signaling Activity Portends Inferior Outcomes in MCL

April 17th 2024
Article
Joshua Brody, MD

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022
Podcast
Dr Ann Tivey

Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma

March 28th 2024
Article
Cancer in the blood outbreak and treatment for malignant cells in a human body caused by carcinogens and genetics with a cancerous cell as an immunotherapy and leukemia or lymphoma symbol and medicalImage Credit: © freshidea - stock.adobe.com

Brexu-Cel Displays Superior Responses vs Pirtobrutinib in Relapsed/Refractory MCL Matching-Adjusted Indirect Comparison

March 22nd 2024
Article